Search for articles or Rx savings
Key takeaways
Gemtesa is a brand-name drug with a retail price of about $692 per month for 30, 75 mg tablets.
A generic form of Gemtesa is not expected to become available until the early 2030s.
Generic overactive bladder drugs such as oxybutynin, mirabegron ER, and tolterodine are more affordable, but only your healthcare provider can determine which medicine is right for you.
Overactive bladder (OAB) can cause urinary frequency, urinary urgency, and even leakage (urinary incontinence). Gemtesa (vibegron) is a beta-3 adrenergic agonist approved by the Food and Drug Administration (FDA) to treat OAB symptoms. However, the retail price of about $692 for 30, 75 mg tablets of brand-name Gemtesa tablets can be prohibitively expensive without insurance coverage or coupons. Many people turn to generic drugs for lower prices, but that only works when a drug is available in generic form. Currently, there is no generic version of Gemtesa available on the market. A generic form may become available in the early 2030s.
Gemtesa generic availability |
|
|---|---|
| Generic name | Vibegron |
| Is there a generic available for sale in the U.S.? | No |
| When will a generic be available? | A generic is expected in the early 2030s, following patent expiration of brand-name Gemtesa |
What are the differences between generic and brand-name Gemtesa?
A generic drug is created to be bioequivalent to the brand-name drug that is already marketed. Bioequivalence means that the generic drug works the same and has the same clinical benefits as the brand-name drug. Generic drugs are considered to be equal substitutes for their brand-name counterparts. They have the same active ingredient and work the same way. They may have differences in their inactive ingredients, but inactive ingredients do not affect how the drug works.
“At this time, there is not a generic form of the medication available,” says JaLorean Hayes, a registered nurse, public health consultant, and founder of Hayes Global Health Strategies. “Gemtesa currently has a number of patents in place that prevent other [manufacturers] from being able to make a medication with the same mechanism of action.”
So, when will generic Gemtesa become available? Not anytime soon. “Most new drugs are protected by patents for about 10–15 years after approval,” says Barbara Sparacino, MD, a triple board-certified physician and founder of The Aging Parent Coach. “Gemtesa was FDA approved in 2020, so we likely won’t see a generic available until the early 2030s unless a patent challenge or licensing deal accelerates the timeline.”
Although there is no generic version of Gemtesa yet, when a generic vibegron does become available, it will work the same way and have the same benefits, although the generic versions may not look exactly the same as brand-name Gemtesa.
How much does generic Gemtesa cost?
Currently, there is no generic version of Gemtesa available. If you are paying for brand-name Gemtesa without insurance or discounts, a typical prescription costs about $692 for 30, 75 mg tablets. You can use a SingleCare discount to pay as low as $442 for this prescription.
Is Gemtesa covered by insurance?
Gemtesa’s manufacturer, Sumitomo Pharma, offers savings programs for people with commercial insurance, such as insurance through an employer. You can check with your specific plan for more information about coverage and costs. If you have prescription coverage through a government program like Medicare or Medicaid, you can check with your specific plan for more details.
How do you get Gemtesa covered by insurance?
Your licensed healthcare provider can send a prescription for Gemtesa to your pharmacy. The pharmacy staff will process the claim electronically and can tell you right away if Gemtesa is covered. Some plans may require prior authorization (PA). This simply means that your plan requires additional information as to why this medicine is medically necessary before they determine if they will cover the prescription. Your healthcare provider’s office can navigate the PA process, if necessary. If you would like to check your coverage at any time, you can call your insurance plan directly or check the most recent formulary online.
Generic alternatives to Gemtesa
Gemtesa isn’t the only FDA-approved treatment for overactive bladder symptoms. If you’re struggling to afford your prescription, there are several Gemtesa alternatives you can ask your prescriber about.
The most similar Gemtesa alternative is Myrbetriq (mirabegron ER), another beta-3 agonist with the same mechanism of action. Both Gemtesa and Myrbetriq increase urinary retention by relaxing the bladder detrusor muscle. The average retail price of brand-name Myrbetriq is $625 for 30, 50 mg tablets, which is about $60 lower than Gemtesa. But Dr. Sparacino points out that it is still a “costly” drug without insurance coverage. Thankfully, a generic version of Myrbetriq (mirabegron) was made available in 2024 and costs $189 for 30, 50 mg extended-release tablets with a SingleCare prescription discount card or coupon.
According to Hayes, there are other affordable alternatives to Gemtesa, including antimuscarinic medications that are available in generic form. Antimuscarinic drugs also work by helping the bladder muscles relax, but common side effects include dry mouth, constipation, drowsiness, and blurred vision. Without insurance coverage, generic antimuscarinic prices range from $104 to $409 per month.
Compare Gemtesa alternatives |
||||
|---|---|---|---|---|
| Drug name | Drug class | Average retail price without insurance | SingleCare price | How to save |
| Myrbetriq (mirabegron) | Beta-3 adrenergic agonist | $625 for 30, 50 mg extended-release tablets | $189 for 30, 50 mg extended-release tablets of generic mirabegron at CVS | Get coupon |
| Fesoterodine ER | Antimuscarinic | $409 for 30, 8 mg extended-release tablets | $35 for 30, 8 mg extended-release tablets at CVS | Get coupon |
| Solifenacin succinate | Antimuscarinic | $394 for 30, 10 mg tablets | $16 for 30, 10 mg tablets at Kroger or Harris Teeter | Get coupon |
| Oxybutynin extended-release (ER) | Antispasmodic | $105 for 30, 10 mg tablets | $10 for 30, 10 mg tablets at Kroger or Harris Teeter | Get coupon |
| Tolterodine tartrate | Antimuscarinic | $203 for 60, 2 mg tablets | $24 for 60, 2 mg tablets at Kroger or Harris Teeter | Get coupon |
Prescription drug prices often change. These are the most accurate medication prices at the time of publishing in ZIP code 23666 as of March 18, 2026. The listed price without insurance references the price of brand-name drugs (unless otherwise specified). The listed SingleCare price references the price of generic drugs if available.
How to save on Gemtesa
“Because Gemtesa is a newer, brand-name medication without a generic alternative, the cost is a significant barrier,” Dr. Sparacino says. Fortunately, healthcare professionals understand that financial strain can impact your ability to stick to your prescription drug plan. It’s a good idea to tell your healthcare provider if you struggle to afford your prescription. You may not know the out-of-pocket cost until you pick up your medication at the pharmacy. Your healthcare provider can offer medical advice on the best treatment for an overactive bladder, even if it is a Gemtesa alternative, taking into consideration other medical conditions, history of serious side effects or allergic reactions, and possible drug interactions with other medications or supplements you may be taking.
If your prescriber determines that Gemtesa is still the best treatment for you, there are still ways to save. One savings tip is to use a SingleCare prescription discount card or Gemtesa coupon, which can lower the out-of-pocket cost of Gemtesa to $442 for 30, 75 mg tablets at participating pharmacies. Simply go to the SingleCare website homepage or the SingleCare app and type in the name of your prescription to compare drug prices and access an instant coupon.
Expert takeaway
“Gemtesa is not available in generic form at this time, but if your insurance does not provide adequate coverage or if you are paying out of pocket, there are other options to consider,” says Karen Berger, Pharm.D., member of the SingleCare Medical Board. “Talk to your healthcare provider about the best treatment for you.”
- Gemtesa, DailyMed (2025)
- Vibegron, MedlinePlus (2025)
- Drugs@FDA: FDA-approved drugs, Food and Drug Administration
- Generic drugs: Questions & answers, Food and Drug Administration(2021)
- Patent and exclusivity for N213006, FDA Orange Book
- Mirabegron, StatPearls (2023)
- Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder, Pharmacology and Therapeutics (2018)